Table 4.
Association between flavonol intake during the trial and colorectal adenoma recurrence among intervention group participants of the Polyp Prevention Trial (n=872)
| Flavonol Quartiles* (in mg/d) | Adenoma Recurrence (T4) |
||||||
|---|---|---|---|---|---|---|---|
| No | Advanced | High Risk | Any | ||||
| n (%) | n (%) | OR (95% CI)† | n (%) | OR (95% CI)† | n (%) | OR (95% CI† | |
| <21.1 | 128 (58.7) | 25 (11.5) | 1.00‡ | 40 (18.3) | 1.00‡ | 90 (41.3) | 1.00‡ |
| 21.1–29.6 | 134 (61.5) | 11 (5.0) | 0.35 (0.16–0.76) | 22 (10.1) | 0.49 (0.27–0.90) | 84 (38.5) | 0.89 (0.60–1.33) |
| 29.7–40.0 | 124 (56.9) | 8 (3.7) | 0.32 (0.13–0.77) | 19 (8.7) | 0.54 (0.28–1.01) | 94 (43.1) | 1.16 (0.78–1.72) |
| >40.0 | 138 (63.3) | 5 (2.3) | 0.17 (0.06–0.50) | 19 (8.7) | 0.51 (0.26–0.98) | 80 (36.7) | 0.96 (0.63–1.46) |
| P-trend§ | 0.0002 | 0.02 | 0.87 | ||||
*
Flavonol intake in quartiles (Q1–Q4) by the mean consumption during the first 3 trial years.
†
Multivariate OR and 95% CI models were adjusted for age tertiles (<58, 58–66, >66 yrs), sex, average BMI (<25, 25.0–29.9, ≥30 kg/m2) and average energy intake (continuous) during the first 3 trial years.
‡
Reference category.
§
The ln-transformed median intakes in mg/d of each quartile were used as a continuous score variable to determine the p value for trend.